ADT vs JBTM

ADT's Advanced Deterministic Scorecard reveals a mixed profile: the Piotroski F-Score of 4/9 indicates borderline financial health, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite solid profitability metrics—such as a 25.65% operating margin and 17.24% ROE—concerns persist due to weak liquidity (Current Ratio: 0.67, Quick Ratio: 0.37) and high leverage (Debt/Equity: 2.16). The stock trades below the analyst target price of $9.48 and near the Graham Number of $8.48, suggesting modest value, but growth is moderate and insider sentiment is neutral. Technical trend is bearish, and recent price performance shows weakness over the past six months despite a strong 1-year earnings surprise record.

JBTM presents a stark contrast between explosive top-line growth and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 2/9. While revenue growth is exceptional at 115.60% YoY and analysts maintain a bullish target price of $183.50, the company is currently struggling with negative profit margins (-1.33%) and negative ROE (-1.65%). Liquidity is a concern with a Quick Ratio of 0.45, and insider sentiment is bearish with significant selling by the CEO and Directors. The stock is a high-growth play with significant underlying financial instability.